All In Biotech

Drug Trial Radar · NCT03971409

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

145

Actual

Start

Jul 8, 2019

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Laura Huppert, MD, BAAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Translational Breast Cancer Research Consortium; Hoosier Cancer Research Network; Array BioPharma; Pfizer; Breast Cancer Research Foundation; Johns Hopkins University; Gilead Sciences
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.

Conditions

  • Stage III Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Invasive Breast Carcinoma
  • Recurrent Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Unresectable Breast Carcinoma

Interventions

  • Anti-OX40 Antibody PF-04518600Biological

    Given IV

  • AvelumabDrug

    Given IV

  • BinimetinibDrug

    Given PO

  • UtomilumabBiological

    Given IV

  • Liposomal DoxorubicinDrug

    Given IV

  • Sacituzumab GovitecanDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate (BORR)Time frame: From treatment initiation until disease progression, an estimated average of 1 year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center

    Birmingham, Alabama

  • University of California, San Francisco

    San Francisco, California

  • Georgetown University

    Washington D.C., District of Columbia

  • University of Chicago Medicine Comprehensive Cancer Center

    Evergreen Park, Illinois

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Duke Cancer Institute

    Durham, North Carolina

  • Abramson Cancer Center, University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Ingram Cancer Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.